                                                                                             SAD & MAD

KT-621 Phase 1a Healthy Volunteer Trial: Safety Summary
Well Tolerated Across All Doses Evaluated and Safety Profile Undifferentiated from Placebo



  • No Serious Adverse Events                            TRAEs by Preferred Term: SAD Cohorts
  • No Severe Adverse Events                                                 SAD          SAD
                                                   AE Term (severity)      Placebo       KT-621
  • No dose dependent pattern in                                            (n=12)       (n=36)
    Treatment Emergent Adverse Events           Headache (mild)            1 (8.3%)          0
    (TEAEs)
  • No Treatment Related AE (TRAE)
                                                         TRAEs by Preferred Term: MAD Cohorts
    reported in >1 participant
                                                                              MAD         MAD
  • No related TEAEs leading to                     AE Term (severity)      Placebo      KT-621
    discontinuation                                                          (n=18)      (n=52)

  • No clinically relevant changes in vital     Nausea (mild)              1 (5.6%)          0
    signs, laboratory tests, and ECGs           Asthenia (mild)                0         1 (1.9%)


                                                                                                     57
